# US 2004/0204473 A1 · Substituted tricyclics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0204473 A1
- Document ID: US20040204473A1
- Status: Published application
- Kind: A1
- Application number: 10/830,380
- Filed: 2004-04-22
- Published: 2004-10-14
- Earliest claimed: 2000-01-07
- Inventors: Ho-Shen Lin; Michael Enrico Richett
- Web page: https://patentgrep.com/patent/US20040204473A1

## CPC

- C07D 209/88: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A class of novel indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

## Claims

### Claim 1

A compound of the formula (I)
104
wherein;
Z is phenyl,
4
R20 is the group -(L)-R80; where, (L)- is a divalent linking group of 1 to 12 atoms selected from carbon, and
hydrogen, where R80 is phenyl;
R21 is a hydrogen or C1-C4 alkyl;
R1 is —CONH2;
R2′ is the group
—O(CH2)tR5′ where
R5′ is the group -(Lh)-(acylamino acid), wherein -(Lh)- is an acylamino acid linker having an acylamino acid linker length of 1 to 7 and t is 1-5;
wherein the (acylamino acid) group is represented by
105
wherein NR9a is hydrogen, (C1-C6) alkyl or (C1-C6) alkoxy;
wherein NR9b is an amino acid residue;
R3′ is selected from hydrogen, C1-C14 alkyl;
or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, or salt, thereof.

### Claim 2

(Cancelled)

### Claim 3

(Cancelled)

### Claim 4 (depends on 1)

A pharmaceutical formulation comprising a compound of formula I as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

### Claim 5

(Cancelled)

### Claim 6 (depends on 1)

A pharmaceutical formulation adapted for the treatment of rheumatoid arthritis, containing a compound of formula I as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

### Claim 7

(Cancelled)

### Claim 8

(Cancelled)

### Claim 9

(Cancelled)

### Claim 10

(Cancelled)

### Claim 11

(Cancelled)

### Claim 12

(Cancelled)

### Claim 13

(Cancelled)

### Claim 14

(Cancelled)

### Claim 15 (depends on 1)

A method of inhibiting sPLA2 which comprises contacting the sPLA2 with a compound of formula I as claimed in claim 1.

### Claim 16

(Cancelled)

### Claim 17

A method of treating sepsis, septic shock, rheumatoid arthritis, osteoarthritis, stroke, apoptosis, asthma, chronic bronchitis, acute bronchitis, cystic fibrosis, inflammatory bowel disease, or pancreatitis which comprises administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of formula I
106
wherein;
Z is cyclohexenyl, or phenyl,
R4 is selected from groups (a), (b) and (c) where;
(a) is 13 (C5-C20)alkyl, —(C5-C20)alkenyl, —(C5-C20)alkynyl, carbocyclic radicals, or heterocyclic radicals, or
(b) is a member of (a) substituted with one or more independently selected non-interfering substituents; or
(c) is the group -(L)-R80; where, (L)—is a divalent linking group of 1 to 12 atoms selected from carbon, hydrogen, oxygen, nitrogen, and sulfur; wherein the combination of atoms in -(L)- are selected from the group consisting of (i) carbon and hydrogen only, (ii) one sulfur only, (iii) one oxygen only, (iv) one or two nitrogen and hydrogen only, (v) carbon, hydrogen, and one sulfur only, and (vi) an carbon, hydrogen, and oxygen only; and where R80 is a group selected from (a) or (b);
R21 is a non-interfering substituent where f is 1-3;
R1 is —NHNH2, —NH2, or —CONH2;
R2′ is the group —O(CH2)tR5′ where
R5′ is (a) —CONR9R10 where R9 and R10 are independently Hydrogen, —(C1-C6)alkyl or —CF3; phenyl or phenyl substituted with —(C1-C6)alkyl; or
(b) -(Lh)-(acylamino acid) group, wherein -(Lh)- is an acylamino acid linker having an “acylamino acid” linker length of 1 to 7 and t is 1-5;
R3′ is selected from non-interfering substituent, carbocyclic radicals, carbocyclic radicals substituted with non-interfering substituents, heterocyclic radicals, and heterocyclic radicals substituted with non-interfering substituents;
or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt, thereof.

### Claim 18

(Cancelled)

### Claim 19 (depends on 10)

A method of claim 10 of alleviating the pathological effects of sepsis, septic shock, adult respiratory distress syndrome, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, rheumatoid arthritis, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondylarthropathris, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enterapathric spondylitis, Juvenile arthropathy or juvenile ankylosing spondylitis, Reactive arthropathy, infectious or post-infectious arthritis, gonoccocal arthritis, Tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with “vasculitic syndromes”, polyarteritis nodosa, hypersensitivity vasculitis, Luegenec's granulomatosis, polymyalgin rheumatica, joint cell arteritis, calcium crystal deposition arthropathris, pseudo gout, non-articular rheumatism, bursitis, tenosynomitis, epicondylitis (tennis elbow), carpal tunnel syndrome, repetitive use injury (typing), miscellaneous forms of arthritis, neuropathic joint disease (charco and joint), hemarthrosis (hemarthrosic), Henoch-Schonlein Purpura, hypertrophic osteoarthropathy, multicentric reticulohistiocytosis, arthritis associated with certain diseases, surcoilosis, hemochromatosis, sickle cell disease and other hemoglobinopathries, hyperlipoproteineimia, hypogammaglobulinemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behat's Disease, systemic lupus erythrematosis, or relapsing polychondritis;
and related diseases which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula I.

### Claim 20

(Cancelled)

### Claim 21

(Cancelled)

### Claim 22

(Cancelled)

### Claim 23

A compound which is selected from the group consisting of;
107
108
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]glycine
109
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]glycine methyl ester
110
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]glycine
111
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-alanine
112
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-alanine methyl ester
113
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-alanine
114
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-leucine
115
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-leucine methyl ester
116
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-leucine
117
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-aspartic acid
118
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-aspartic acid dimethyl ester
119
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-aspartic acid
120
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-glutamic acid
121
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-glutamic acid dimethyl ester
122
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-glutamic acid
123
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-methionine
124
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-methionine methyl ester
125
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-methionine
126
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-phenylalanine
127
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-phenylalanine methyl ester
128
and
N-[[[5-Carbamoyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetyl]-L-phenylalanine
129
or a pharmaceuticallt acceptable racemate, solvate, tautomer, optical isomer, prodrug derivative or salt thereof.

### Claim 24

(Cancelled)
